| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Biochemistry and Biophysics, Lineberger Comprehensive Cancer Center, Curriculum in Genetics and Molecular Biology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 [A. V., M. V., S. G. C.]; Laboratories of Molecular Genetics [A. U., T. A. K.] and Molecular Carcinogenesis [J. I. R., J. C. B.], National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709; and Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [T. C. H.]
Defects in mismatch repair are associated with cisplatin resistance, and several mechanisms have been proposed to explain this correlation. It is hypothesized that futile cycles of translesion synthesis past cisplatin-DNA adducts followed by removal of the newly synthesized DNA by an active mismatch repair system may lead to cell death. Thus, resistance to platinum-DNA adducts could arise through loss of the mismatch repair pathway. However, no direct link between mismatch repair status and replicative bypass ability has been reported. In this study, cytotoxicity and steady-state chain elongation assays indicate that hMLH1 or hMSH6 defects result in 1.5–4.8-fold increased cisplatin resistance and 2.5–6-fold increased replicative bypass of cisplatin adducts. Oxaliplatin adducts are not recognized by the mismatch repair complex, and no significant differences in bypass of oxaliplatin adducts in mismatch repair-proficient and -defective cells were found. Defects in hMSH3 did not alter sensitivity to, or replicative bypass of, either cisplatin or oxaliplatin adducts. These observations support the hypothesis that mismatch repair defects in hMutL
and hMutS, but not in hMutSß, contribute to increased net replicative bypass of cisplatin adducts and therefore to drug resistance by preventing futile cycles of translesion synthesis and mismatch correction.
1 Supported in part by USPHS Grant CA34082 and a grant from Sanofi Pharmaceuticals.
2 These authors contributed equally to this work.
3 To whom requests for reprints should be addressed, at Department of Biochemistry and Biophysics, University of North Carolina, 515 Mary Ellen Jones Building, Chapel Hill, NC 27599-7260. Phone: (919) 966-3286; Fax: (919) 966-2852; E-mail: Stephen_Chaney@med.unc.edu.
Received 3/ 2/98. Accepted 6/17/98.
This article has been cited by other articles:
|
|
 |
|
  A. Zaanan, P. Cuilliere-Dartigues, A. Guilloux, Y. Parc, C. Louvet, A. de Gramont, E. Tiret, S. Dumont, B. Gayet, P. Validire, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin Ann. Onc., October 15, 2009; (2009) mdp383v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Topping, J. C. Wilkinson, and K. D. Scarpinato Mismatch Repair Protein Deficiency Compromises Cisplatin-induced Apoptotic Signaling J. Biol. Chem., May 22, 2009; 284(21): 14029 - 14039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R Kelland DNA Repair Enzymes and Platinum Drug Resistance in Tumors Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 209 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Spunt, B. B. Freeman III, C. A. Billups, V. McPherson, R. B. Khan, C. B. Pratt, and C. F. Stewart Phase I Clinical Trial of Oxaliplatin in Children and Adolescents With Refractory Solid Tumors J. Clin. Oncol., June 1, 2007; 25(16): 2274 - 2280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ryu, J. Viguier, and F. Praz Genetic Effect of ERCC1 Codon 118 Polymorphism and Confounding Factors Clin. Cancer Res., August 1, 2006; 12(15): 4784 - 4785. [Full Text] [PDF]
|
|
|
|
 |
|
 X. Lin and S. B. Howell DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance Mol. Cancer Ther., May 1, 2006; 5(5): 1239 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Viens, T. Petit, A. Yovine, P. Bougnoux, G. Deplanque, P.-H. Cottu, R. Delva, J.-P. Lotz, S. V. Belle, J.-M. Extra, et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients Ann. Onc., March 1, 2006; 17(3): 429 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Lin, J. Trang, T. Okuda, and S. B. Howell DNA Polymerase {zeta} Accounts for the Reduced Cytotoxicity and Enhanced Mutagenicity of Cisplatin in Human Colon Carcinoma Cells That Have Lost DNA Mismatch Repair Clin. Cancer Res., January 15, 2006; 12(2): 563 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hata, H. Yamamoto, C. Y. Ngan, M. Koi, A. Takagi, B. Damdinsuren, M. Yasui, Y. Fujie, T. Matsuzaki, H. Hemmi, et al. Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells Mol. Cancer Ther., October 1, 2005; 4(10): 1585 - 1594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Risinger, G. L. Maxwell, G. V.R. Chandramouli, O. Aprelikova, T. Litzi, A. Umar, A. Berchuck, and J. C. Barrett Gene Expression Profiling of Microsatellite Unstable and Microsatellite Stable Endometrial Cancers Indicates Distinct Pathways of Aberrant Signaling Cancer Res., June 15, 2005; 65(12): 5031 - 5037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Clodfelter, M. B. Gentry, and K. Drotschmann MSH2 missense mutations alter cisplatin cytotoxicity and promote cisplatin-induced genome instability Nucleic Acids Res., June 9, 2005; 33(10): 3323 - 3330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Calmann and M. G. Marinus MutS inhibits RecA-mediated strand exchange with platinated DNA substrates PNAS, September 28, 2004; 101(39): 14174 - 14179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bassett, N. M. King, M. F. Bryant, S. Hector, L. Pendyala, S. G. Chaney, and M. Cordeiro-Stone The Role of DNA Polymerase {eta} in Translesion Synthesis Past Platinum-DNA Adducts in Human Fibroblasts Cancer Res., September 15, 2004; 64(18): 6469 - 6475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. I. Wu, J. A. Brown, M. J. Dorie, L. Lazzeroni, and J. M. Brown Genome-Wide Identification of Genes Conferring Resistance to the Anticancer Agents Cisplatin, Oxaliplatin, and Mitomycin C Cancer Res., June 1, 2004; 64(11): 3940 - 3948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Hayward, J. S. Macpherson, J. Cummings, B. P. Monia, J. F. Smyth, and D. I. Jodrell Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect Mol. Cancer Ther., February 1, 2004; 3(2): 169 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Mita, E. Chatelut, M. Bekradda, P. Soulie, P. Canal, J.-L. Misset, E. Cvitkovic, and R. Bugat Phase I and pharmacological study of an oxaliplatin and carboplatin combination in advanced malignancies Ann. Onc., December 1, 2003; 14(12): 1776 - 1782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Gazzoli and R. D. Kolodner Regulation of the Human MSH6 Gene by the Sp1 Transcription Factor and Alteration of Promoter Activity and Expression by Polymorphisms Mol. Cell. Biol., November 15, 2003; 23(22): 7992 - 8007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Bataille, P Rummele, W Dietmaier, D Gaag, F Klebl, A Reichle, P Wild, F Hofstadter, and A Hartmann Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer Mol. Pathol., October 1, 2003; 56(5): 286 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. Takimoto, S. C. Remick, S. Sharma, S. Mani, R. K. Ramanathan, J. Doroshow, A. Hamilton, D. Mulkerin, M. Graham, G. F. Lockwood, et al. Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study J. Clin. Oncol., July 15, 2003; 21(14): 2664 - 2672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Fourrier, P. Brooks, and J.-M. Malinge Binding Discrimination of MutS to a Set of Lesions and Compound Lesions (Base Damage and Mismatch) Reveals Its Potential Role as a Cisplatin-damaged DNA Sensing Protein J. Biol. Chem., May 30, 2003; 278(23): 21267 - 21275. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Augusto-Pinto, S. M. R. Teixeira, S. D. J. Pena, and C. R. Machado Single-Nucleotide Polymorphisms of the Trypanosoma cruzi MSH2 Gene Support the Existence of Three Phylogenetic Lineages Presenting Differences in Mismatch-Repair Efficiency Genetics, May 1, 2003; 164(1): 117 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Petit, D. J. Bearss, D. A. Troyer, R. M. Munoz, and J. J. Windle p53-independent Response to Cisplatin and Oxaliplatin in MMTV-ras Mouse Salivary Tumors Mol. Cancer Ther., February 1, 2003; 2(2): 165 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Zhang, X. Lu, X. Zhang, C. A. Peterson, and R. J. Legerski hMutS{beta} Is Required for the Recognition and Uncoupling of Psoralen Interstrand Cross-Links In Vitro Mol. Cell. Biol., April 1, 2002; 22(7): 2388 - 2397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Schenk, A. W. M. Boersma, M. Brok, H. Burger, G. Stoter, and K. Nooter Inactivation of the Saccharomyces cerevisiae SKY1 Gene Induces a Specific Modification of the Yeast Anticancer Drug Sensitivity Profile Accompanied by a Mutator Phenotype Mol. Pharmacol., March 1, 2002; 61(3): 659 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, and E. Cvitkovic Cellular and Molecular Pharmacology of Oxaliplatin Mol. Cancer Ther., January 1, 2002; 1(3): 227 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kondo, R. Safaei, M. Mishima, H. Niedner, X. Lin, and S. B. Howell Hypoxia-induced Enrichment and Mutagenesis of Cells That Have Lost DNA Mismatch Repair Cancer Res., October 1, 2001; 61(20): 7603 - 7607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pepponi, G. Graziani, S. Falcinelli, P. Vernole, L. Levati, P. M. Lacal, E. Pagani, E. Bonmassar, J. Jiricny, and S. D'Atri hMSH3 overexpression and cellular response to cytotoxic anticancer agents Carcinogenesis, August 1, 2001; 22(8): 1131 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. S. Xu, L. Narayanan, B. Dunklee, R. M. Liskay, and P. M. Glazer Hypermutability to Ionizing Radiation in Mismatch Repair-deficient, Pms2 Knockout Mice Cancer Res., May 1, 2001; 61(9): 3775 - 3780. [Abstract] [Full Text]
|
|
|
|
|
|
X. Lin, K. Ramamurthi, M. Mishima, A. Kondo, and S. B. Howell p53 Interacts with the DNA Mismatch Repair System to Modulate the Cytotoxicity and Mutagenicity of Hydrogen Peroxide Mol. Pharmacol., April 13, 2001; 58(6): 1222 - 1229. [Abstract] [Full Text]
|
|
|
|
|
|
X. Lin, K. Ramamurthi, M. Mishima, A. Kondo, R. D. Christen, and S. B. Howell p53 Modulates the Effect of Loss of DNA Mismatch Repair on the Sensitivity of Human Colon Cancer Cells to the Cytotoxic and Mutagenic Effects of Cisplatin Cancer Res., February 1, 2001; 61(4): 1508 - 1516. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Woynarowski, S. Faivre, M. C.S. Herzig, B. Arnett, W. G. Chapman, A. V. Trevino, E. Raymond, S. G. Chaney, A. Vaisman, M. Varchenko, et al. Oxaliplatin-Induced Damage of Cellular DNA Mol. Pharmacol., November 1, 2000; 58(5): 920 - 927. [Abstract] [Full Text]
|
|
|
|
|
|
S. E. Berry, T. W. Davis, J. E. Schupp, H.-S. Hwang, Niels de Wind, and T. J. Kinsella Selective Radiosensitization of Drug-resistant MutS Homologue-2 (MSH2) Mismatch Repair-deficient Cells by Halogenated Thymidine (dThd) Analogues: Msh2 Mediates dThd Analogue DNA Levels and the Differential Cytotoxicity and Cell Cycle Effects of the dThd Analogues and 6-Thioguanine Cancer Res., October 1, 2000; 60(20): 5773 - 5780. [Abstract] [Full Text]
|
|
|
|
|
|
M. Zeng, L. Narayanan, X. S. Xu, T. A. Prolla, R. M. Liskay, and P. M. Glazer Ionizing Radiation-induced Apoptosis via Separate Pms2- and p53-dependent Pathways Cancer Res., September 1, 2000; 60(17): 4889 - 4893. [Abstract] [Full Text]
|
|
|
|
|
|
R. A. Nagourney, J. S. Link, J. B. Blitzer, C. Forsthoff, and S. S. Evans Gemcitabine Plus Cisplatin Repeating Doublet Therapy in Previously Treated, Relapsed Breast Cancer Patients J. Clin. Oncol., June 11, 2000; 18(11): 2245 - 2249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vaisman and S. G. Chaney The Efficiency and Fidelity of Translesion Synthesis past Cisplatin and Oxaliplatin GpG Adducts by Human DNA Polymerase beta J. Biol. Chem., April 21, 2000; 275(17): 13017 - 13025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Johnson, M. L. Mierzwa, S. P. Fink, and L. J. Marnett MutS Recognition of Exocyclic DNA Adducts That Are Endogenous Products of Lipid Oxidation J. Biol. Chem., September 17, 1999; 274(38): 27112 - 27118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Moreland, M. Illand, Y. T. Kim, J. Paul, and R. Brown Modulation of Drug Resistance Mediated by Loss of Mismatch Repair by the DNA Polymerase Inhibitor Aphidicolin Cancer Res., May 1, 1999; 59(9): 2102 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Kern, J. Braess, B. Bottger, C. C. Kaufmann, W. Hiddemann, and E. Schleyer Oxaliplatin Pharmacokinetics during a Four-Hour Infusion Clin. Cancer Res., April 1, 1999; 5(4): 761 - 765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Berardini, A. Mazurek, and R. Fishel The Effect of O6-Methylguanine DNA Adducts on the Adenosine Nucleotide Switch Functions of hMSH2-hMSH6 and hMSH2-hMSH3 J. Biol. Chem., September 1, 2000; 275(36): 27851 - 27857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Z. Zdraveski, J. A. Mello, C. K. Farinelli, J. M. Essigmann, and M. G. Marinus MutS Preferentially Recognizes Cisplatin- over Oxaliplatin-modified DNA J. Biol. Chem., January 4, 2002; 277(2): 1255 - 1260. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
